Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

The European Union is negotiating with Merck & Co Inc (NYSE: MRK) and Pfizer Inc (NYSE: PFE) over possible contracts to supply COVID-19 drugs, an EU official told Reuters. Both the companies have developed antiviral pills that have shown promising efficacy in trials of adults with COVID-19 who are at high risk of serious illness, with Pfizer's at 89% and Merck's around 50%.

Merck Ahead Of Pfizer In Talks With Europe For COVID-19 Pills: Reuters

BioNTech SE

Moderna

Pfizer

Now that the COVID-19 vaccine is available to virtually everyone in the country, I have one favorite among vaccine stocks after earnings. The post Are Vaccine Stocks A Buy On Earnings?

Are Vaccine Stocks A Buy On Earnings?

The pharma giant's stock took flight last month after its oral COVID-19 therapy hit the mark in a pivotal trial.

Here's Why Merck Stock Vaulted Higher in October

CBRE Group

Gartner

Nucor

ON Semiconductor

Tesla

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

The stock price of Merck & Co., Inc. (NYSE: MRK) fell over 9% in the previous trading session. This is why it happened.

Merck (MRK) Stock: Why The Price Fell

AbbVie

Bristol-Myers

These companies could both diversify your portfolio and boost your dividend income.

3 Best Biotech Stocks to Buy in November

Boeing

Disney

Visa

Merck shares fell sharply on news that a competing COVID-19 pill from Pfizer is more effective, but employers reported a big increase in jobs growth last month, pushing the index higher.

Dow Jones Gains 300 Points on Jobs Report, Merck Shares Slammed on Pfizer's COVID Pill Results

With promising updates from Pfizer Inc. ( PFE , Financial) regarding the effectiveness of its oral Covid-19 pills, consumers and investors alike are continuing to carefully watch the health care space.

2 Health Care Stocks to Consider on Covid-19 Treatment Updates

Pfizer's stock soars after it delivers groundbreaking results for its COVID-19 oral antiviral candidate, PAXLOVID.

Pfizer stock jumps, Moderna, Merck tumble

Shares of Merck & Co. MRK, -9.62% tumbled 9.5% in midday trading Friday, putting them on track to suffer the biggest one-day drop since January 2005, after Pfizer Inc. PFE, +8.34% released data on a pill to treat COVID-19 that showed greater efficacy than Merck's. The stock's price decline of $8.61 was shaving about 57 points off the Dow Jones Industrial Average's DJIA, +0.63% price, while the Dow rallied 246 points, or 0.7%.

Merck stock's biggest selloff in nearly 17 years is cutting close to 60 points off the Dow's price

Regeneron Pharmaceuticals

Pfizer jumped 8% Friday morning, while Moderna dropped 17.8%, Regeneron 6.2% and Merck 9%.

Billions Wiped From Covid Pharma Heavyweights—Including Moderna, Regeneron, Merck—As Pfizer's Antiviral Pill Triggers Selloff

Pfizer plans to seek the Food and Drug Administration's OK this month for the pill, with doses potentially ready for delivery this year.

Pfizer soars 10% on strong results from COVID-19 pill study, while Moderna and Merck tumble

Kraft Heinz

They have solid fundamentals, their shares are cheap, and they also pay dividends.

2 Buffett Stocks That Look Like Great Buys in November

Vaxart

Only two of the pills are slated to be therapeutic.

3 COVID Pill Stocks That Might Be Game-Changers

Merck & Co. Inc. shares MRK, +2.10% slid 10% in premarket trading Friday, after Pfizer Inc. PFE, -1.31% said its antiviral treatment for COVID-19 was more effective in reducing the risk of hospitalization or death in high-risk adults than numbers reported recently by Merck for its antiviral. Pfizer said interim data from a Phase 2/3 trial of its oral antiviral treatment for COVID-19 reduced the risk of hospitalization or death by 89% in non-hospitalized high-risk adults with COVID.

Merck shares slide premarket as Pfizer soars on data from trial of rival COVID antiviral treatment

The company announced it has received approval for another Keytruda indication in the E.U.

Merck Receives Another Boost for Its Top-Selling Drug

An anti-coronavirus treatment in pill form manufactured by pharma giant Merck has become the first to be approved for use after the UK gave it the go-ahead today. Britain's medicines agency, the MHRA, said the drug could be given to people with mild to moderate COVID-19 at risk of developing a severe illness such as heart disease.

Merck Covid-19 treatment approved in UK as infection rate soars

In the U.S., the Food and Drug is slated to convene on November 30 to decide whether to green light the oral pill for emergency use after examining the safety and efficacy data of the pill.

Merck's Covid Pill Molnupiravir Authorized For First Time In The U.K.

Amplify Travel Tech ETF

Global X Autonomous & Electric Vehicles ETF

SPDR S&P 600 Small Cap ETF

SPDR S&P Oil & Gas Exploration & Production ETF

SPDR S&P Retail ETF

November kicked off on a solid note after a solid October rally. Better-than-expected corporate earnings boosted the U.S. stocks.

5 ETFs Strategies to Play in November

Following a solid performance in Q3, Merck raised its full year outlook for sales to be in the range of $47.4 billion and $47.9 billion, compared to its earlier estimate of $46.4 billion to $47.4 billion. Looking at the bottom line, the company now expects its adjusted EPS to be in the range of.

What's Next For Merck Stock After An Upbeat Q3?

An antiviral pill found to be effective at treating Covid-19 has been approved by Britain's medicines regulator Thursday in a potentially game-changing way of treating the virus.

Merck's Covid pill approved by UK regulator, a potential game-changer in fighting the pandemic

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization to Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' molnupiravir (MK-4482) for COVID-19. The approval marks the first oral antiviral medicine authorized to treat mild-to-moderate COVID-19 in adults who have at least one risk factor for developing severe illness.

Britain Approves First Oral COVID-19 Antiviral From Merck

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback's Molnupiravir Oral COVID-19 Antiviral Medicine Receives First Authorization in the World from U.K.'s Regulatory Agency

Merck and Ridgeback's Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World

The U.K. Medicines and Healthcare products Regulatory Agency said it's approved molnupiravir, which is now going by the name Lagevrio. The U.K. health secretary, Sajid Javid, said it's the first country to approve an antiviral that can be taken at home for COVID-19.

News for Merck Stock (MRK)